iZafe Group AB Series B (ST:IZAFE-B) — Market Cap & Net Worth
Market Cap & Net Worth: iZafe Group AB Series B (IZAFE-B)
iZafe Group AB Series B (ST:IZAFE-B) has a market capitalization of $12.36 Million (Skr114.90 Million) as of September 19, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #26600 globally and #560 in its home market, demonstrating a -14.24% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying iZafe Group AB Series B's stock price Skr0.28 by its total outstanding shares 405991337 (405.99 Million). Also see IZAFE-B asset base for a full breakdown of the balance sheet.
iZafe Group AB Series B Market Cap History: 2015 to 2026
iZafe Group AB Series B's market capitalization history from 2015 to 2026. Data shows change from $88.26 Million to $12.36 Million (-14.67% CAGR). Also see iZafe Group AB Series B operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Index Memberships
iZafe Group AB Series B is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$15.23 Billion | 0.08% | #147 of 281 |
Weight: iZafe Group AB Series B's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
iZafe Group AB Series B Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how iZafe Group AB Series B's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check iZafe Group AB Series B (IZAFE-B) share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
3.50x
iZafe Group AB Series B's market cap is 3.50 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $517.74 Million | $155.00K | -$4.27 Million | 3340.26x | N/A |
| 2018 | $265.21 Million | $7.57 Million | -$11.31 Million | 35.03x | N/A |
| 2019 | $100.71 Million | $14.33 Million | -$23.12 Million | 7.03x | N/A |
| 2020 | $131.51 Million | $8.90 Million | -$12.75 Million | 14.77x | N/A |
| 2021 | $35.35 Million | $442.00K | -$36.27 Million | 79.97x | N/A |
| 2022 | $12.71 Million | $729.00K | -$23.53 Million | 17.44x | N/A |
| 2023 | $12.58 Million | $1.82 Million | -$32.17 Million | 6.91x | N/A |
| 2024 | $9.35 Million | $7.95 Million | -$20.51 Million | 1.18x | N/A |
| 2025 | $20.97 Million | $5.99 Million | -$16.68 Million | 3.50x | N/A |
Competitor Companies of IZAFE-B by Market Capitalization
Companies near iZafe Group AB Series B in the global market cap rankings as of September 19, 2026. Review iZafe Group AB Series B tangible book value ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to iZafe Group AB Series B by market ranking:
- Intuitive Surgical Inc (NASDAQ:ISRG): Ranked #177 globally with a market cap of $135.72 Billion USD.
- EssilorLuxottica S. A. (PA:EL): Ranked #366 globally with a market cap of $75.25 Billion USD ( €64.36 Billion EUR).
- ESSILORLUXOTTICA 1/2/O.N. (F:ESLC): Ranked #422 globally with a market cap of $67.43 Billion USD ( €57.68 Billion EUR).
- HOYA CORP. ADR/ 1 O.N. (F:HYB0): Ranked #545 globally with a market cap of $50.37 Billion USD ( €43.09 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #177 | Intuitive Surgical Inc | NASDAQ:ISRG | $135.72 Billion | $393.33 |
| #366 | EssilorLuxottica S. A. | PA:EL | $75.25 Billion | €139.00 |
| #422 | ESSILORLUXOTTICA 1/2/O.N. | F:ESLC | $67.43 Billion | €68.50 |
| #545 | HOYA CORP. ADR/ 1 O.N. | F:HYB0 | $50.37 Billion | €150.00 |
iZafe Group AB Series B Historical Marketcap From 2015 to 2026
Between 2015 and today, iZafe Group AB Series B's market cap moved from $88.26 Million to $ 12.36 Million, with a yearly change of -14.67%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr12.36 Million | -41.04% |
| 2025 | Skr20.97 Million | +124.30% |
| 2024 | Skr9.35 Million | -25.69% |
| 2023 | Skr12.58 Million | -1.03% |
| 2022 | Skr12.71 Million | -64.03% |
| 2021 | Skr35.35 Million | -73.12% |
| 2020 | Skr131.51 Million | +30.59% |
| 2019 | Skr100.71 Million | -62.03% |
| 2018 | Skr265.21 Million | -48.78% |
| 2017 | Skr517.74 Million | +50.00% |
| 2016 | Skr345.16 Million | +291.09% |
| 2015 | Skr88.26 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of iZafe Group AB Series B was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $12.36 Million USD |
| MoneyControl | $12.36 Million USD |
| MarketWatch | $12.36 Million USD |
| marketcap.company | $12.36 Million USD |
| Reuters | $12.36 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About iZafe Group AB Series B
iZafe Group AB (publ), a medical technology company, engages in the research, development, and marketing of digital medical solutions and services for safer drug management at home. The company provides Dosell, an automated medication dispenser that handles medication pouches, smart pillboxes, facilitates and enables independent medication, and reminds and alerts in the scheduled doses. It also o… Read more